| |
All files in PDF format.
Recent Scientific Publications on Antineoplastons by S.R. Burzynski
Abstracts of Recent Scientific Presentations on Antineoplastons by S.R. Burzynski
Selected Scientific Publications on Antineoplastons by Independent Scientists
RECENT SCIENTIFIC PUBLICATIONS ON ANTINEOPLASTONS BY S.R. BURZYNSKI AND
ASSOCIATES
PEER-REVIEWED BOOK CHAPTERS, MONOGRAPHS AND ABSTRACTS
2004-2007
A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma.
Burzynski, S.R., Weaver, R., Szymkowski, B. Neuro-Oncology 2007; 9:536
Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells.
Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Neuro-Oncology 2007; 9:482
Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas.
Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Neuro-Oncology 2007; 9:206
Targeted Therapy for Brain Tumors.
Burzynski, S.R., In: Yang A.V.: Brain Cancer: Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006
Treatments for Astrocytoma in Children: Current and Emerging Strategies
Burzynski, S.R. Pediatric Drugs, 2006; 8:167-178
Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1.
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopolov, V.; Neurooncol. 2006; 10:466
Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report.
Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V. Neurooncol. 2006; 10:439
Targeted Therapy with Antineoplastons A10 and AS2-1 of High-Grade, Recurrent and Progressive Brainstem Glioma.
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B.; Integrative Cancer Therapies, 2006; 40-47
Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas.
Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G; Neurooncol. 2005; 7:300
Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP.
Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Neurooncol. 2005; 7:299
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 AS2-1.
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Integrative Cancer Therapies, 2005; 4(2): 168-177
Antineoplastons In Dairy Products.
Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L.; Journal of Applied Nutrition, 2004; 54; 1-8
Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. A preliminary report.
Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.; Neurooncol., 2004; 6: 427
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma.
Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.; Neurooncol., 2004; 6: 387
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report.
Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.; Drugs R&D, 2004; 5 (6): 315-326
The Present State of Antineoplaston Research.
Burzynski, S.R.; Integrative Cancer Therapies, 2004; 3: 47-58.
ABSTRACTS OF RECENT SCIENTIFIC PRESENTATIONS ON ANTINEOPLASTONS
BY S.R. BURZYNSKI AND ASSOCIATES
PRESENTED AT MAJOR MEDICAL CONVENTIONS
2004-2006
Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas.
Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Presented at: The European Association for Neuro Oncology: 7th Congress; September 14-17, 2006; Vienna, Austria.
Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas.
Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Presented at: 12th International Symposium on Pediatric Neuro-Oncology; June 6-9, 2006; Nara, Japan.
Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brainstem glioma.
Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.
Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate.
Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.
SELECTED SCIENTIFIC PUBLICATIONS ON ANTINEOPLASTONS AND THEIR ACTIVE INGREDIENTS BY INDEPENDENT SCIENTISTS
National Cancer Institute, Bethesda, Maryland
National Cancer Institute’s Evaluation of Unconventional Cancer Treatments.
Hawkins, M.G., Friedman, M.A.; J Natl Cancer Inst. 1992; 84: 22, 1699-702
Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion.
Shack, S., Chen, L.C., Miller, A.C., Danesi, R., Samid, D.; Internat J Cancer. 1995; 63: 124-9
Medical College of Georgia, Augusta, Georgia
Antiestrogenic piperidinediones designed prospectively using computer graphics and energy calculations of DNA-ligand complexes.
Hendry, L.B., Chung, K.C., Copland, J.A., Mahesh, V. B.; J. Steroid Biochem Molec Biol. 1994; 48: 495-505
Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2, 6-piperidinedione and its para-hydroxy analog.
Copland, J.A., Hendry, L.B., Chu, C.K., Wood, J.C., Wrenn, R.W., Pantazis, C.G., Mahesh, V.B.; J Steroid Biochem Molec Biol. 1993; 46: 451-62
Structure-activity relationships, molecular modeling and antitumor activity of phenylacetylamino-2, 6-piperidinediones.
Hendry, L.B., Chu, C.K., Huang, J.C., Wood, J.A., Copland, J.A., Mahesh, V.B.; Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1991; Munich, Germany
Mayo clinic and Mayo Foundation, Rochester, Minnesota
Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.
Witzig, T. E., Timm, M., Stenson, M., Svingen, P. A., Kaufmann, S. H.; Clin Cancer Res. 2000; 6: 681-92
University of Virginia, Charlottesville, Virginia
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.
Gorospe, M., Shack, S., Guyton, K.Z., Samid, D., Holbrook, N.J.; Cell Growth Differ. 1996; 7: 1609-15
Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells.
Gore, S.D., Samid, D., Weng, L.J.; Clin Cancer Res. 1997; 3: 1755-62
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Prasanna, P., Thibault, A., Liu, L., Samid, D.; J Neurochem. 1996; 66: 710-16
Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.
Danesi, R., Nardini, D., Basolo, F., Del Tacca, M., Samid, D., and Myers, C.E.; Mol Pharmacol. 1996; 49, 972-9
Imperial College of London, UK
Mutagenicity studies on antineoplaston A10, AS2-1 and AS2-5 in cultures of Salmonella typhimurium (Ames test).
Gingold, E., Sear, C.H.J., Smith, R.N.; Presented at the 15th International Congress of Chemotherapy; July 1987; Istanbul, Turkey
The crystal and molecular structure of antineoplaston A10.
Williams, D.J.; Presented at the 10th International Congress of Pharmacology, August 1987, Sydney, Australia
University of Kurume Medical School, Japan
Antineoplaston Induces G1 arrest by PKCa and MAPK pathway in SKBT-3 breast cancer cells.
Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H.; Oncology Reports 2005; 14: 489-494
Effects of antineoplaston AS2-1 against post-operative lung metastases in orthtopically implanted colon cancer in nude rat.
Matono, K., Ogata, Y., Tsuda, H., Shirouzu, K.; Oncology Reports. 2005; (13): 389-395
The preventive effect of antineoplaston AS2-1 on HCC recurrence.
Tsuda, H., Sata, M., Kumabe, T., Uhida, M., Hara, H.; Oncology Reports 2002; 10: 391-397
A novel strategy for remission induction and maintenance in cancer therapy.
Tsuda, H., Sata, M., Ijuuin, H., Kumabe, T., Uchia, M., Ogou, Y., Akagi, Y., Schirouzu, K., Hara, H., Nakashima, Y.; Oncology Reports 2002; 9: 65-68
University of Turin, University of Piza, Italy
Biological effects in vitro of A10.
Silvestro, L., Viano, I., Bertelli, A.A.E., Fantozzi, R., Dianzani, C.; Internat J Tissue Reactions. 1990; 12 (suppl): 57-60
Institute of Human Molecular and Cellular Oncology, University Paris Nord, France
Tumor growth inhibition. apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.
Adam, L., Crepin, M., Israel, L.; Cancer Res. 1997; 57: 1023-9
Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice.
Adam, L., Crépin, M., Savin, C., Israël, L.; Cancer Res. 1995; 55: 5156-160
International Biomedisch Centrum, Luende, Netherlands
Antineoplaston therapy in a private out-patient environment.
Van der Schaar, P.J.; Presented at the 18th International Congress of Chemotherapy; June 1993; Stockholm, Sweden
Other independent scientists
Novel piperidiedione analogs as inhibitors of breast cancer cell growth.
Abou-Zeid, L., El-Mowafy, A.M., El-Ashmawy, M.B., Hendry, L.B., Abdelal A. M., Badria, F.A.; Arch. Pharm. Pharm. Med. Chem. 2000; 333; 431-434
Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma.
Harrison, L.E., Wojciechowicz, D.C., Brennan, M.F., Paty, P.B.; Surgery 1998; 124 (3): 541-50 |
